Symbol | Exchange | Currency |
|---|
April 7 (Reuters) - Imugene Ltd IMU.AX :* IMUGENE- COHORT REVIEW COMMITTEE CONFIRMED PHASE I CLINICAL TRIAL OF PD1-VAXX, WILL PROCEED TO THIRD AND FINAL HIGHEST DOSE COHORT
Nov 2 (Reuters) - Imugene Ltd IMU.AX :* IMUGENE RECEIVES FDA IND APPROVAL FOR PD1-VAXX TRIAL IN USA* U.S. FDA APPROVAL ALLOWS CO TO INITIATE RECRUITMENT, DOSING IN USA PHASE I...
Sept 9 (Reuters) - Imugene Ltd IMU.AX :* IMUGENE LTD - SECURES $5.7 MILLION OPTION UNDERWRITING AGREEMENT
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highsBoth Iran, US likely looking...
Imugene Limited is an Australia-based clinical-stage immuno-oncology company. The Company is engaged in developing a range of new immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its product pipeline includes multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies, such as CAR T’s for solid tumors. Its PD-1 B-cell immunotherapy (PD1-Vaxx), aims to induce the body to produce polyclonal antibodies that block PD-1 signaling, and thus produce an anticancer effect. Its HER-Vaxx is a B-cell activating cancer immunotherapy designed to treat tumors that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. Its clinical trial candidates include VAXINIA (CF33 + hNIS), CHECKvacc (CF33 + hNIS + PD-L1), B-Vaxx and others.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Strong Sell | Strong Sell | Sell | Strong Buy |
| Technical Indicators | Strong Sell | Strong Sell | Strong Sell | Sell | Sell |
| Summary | Strong Sell | Strong Sell | Strong Sell | Sell | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 8.16 | 8.26 | 8.11 | -0.12 | -1.45% | 2.60M | Sydney | |||
| 0.55 | 0.55 | 0.54 | -0.01 | -1.80% | 2.47M | Sydney | |||
| 0.89 | 0.98 | 0.88 | -0.14 | -13.24% | 1.05M | Sydney | |||
| 0.345 | 0.35 | 0.33 | -0.005 | -1.43% | 503.46K | Sydney | |||
| 6.93 | 7.09 | 6.87 | +0.150 | +2.21% | 6.62M | Sydney | |||
| 1.705 | 1.72 | 1.65 | -0.015 | -0.87% | 10.17M | Sydney | |||
| 4.77 | 4.81 | 4.77 | -0.05 | -1.04% | 4.97M | Sydney | |||
| 7.77 | 7.88 | 7.73 | -0.330 | -4.07% | 6.96M | Sydney | |||
| 4.30 | 4.36 | 4.265 | -0.170 | -3.80% | 3.57M | Sydney | |||
| 0.25 | 0.257 | 0.24 | -0.010 | -3.85% | 48.34M | Sydney | |||
| 19.08 | 19.12 | 18.72 | -0.150 | -0.78% | 7.15M | Sydney | |||
| 0.71 | 0.72 | 0.70 | 0.000 | 0.00% | 519.99K | Sydney | |||
| 7.96 | 8.73 | 7.65 | -0.86 | -9.75% | 2.70M | Sydney | |||
| 25.51 | 25.80 | 25.42 | -0.29 | -1.12% | 491.49K | Sydney | |||
| 5.48 | 5.49 | 5.30 | +0.10 | +1.86% | 22.48K | Sydney |